Aaron N Hata Selected Research

Tyrosine Kinase Inhibitors

12/2022	MicroRNA-21 guide and passenger strand regulation of adenylosuccinate lyase-mediated purine metabolism promotes transition to an EGFR-TKI-tolerant persister state.
1/2022	Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer.
11/2020	Modeling Resistance and Recurrence Patterns of Combined Targeted-Chemoradiotherapy Predicts Benefit of Shorter Induction Period.
1/2019	Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity.
1/2019	Patient-Specific Tumor Growth Trajectories Determine Persistent and Resistant Cancer Cell Populations during Treatment with Targeted Therapies.
12/2018	Landscape of Acquired Resistance to Osimertinib in EGFR-Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion.
1/2018	Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer.
9/2016	EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Aaron N Hata Research Topics

Disease

51	Neoplasms (Cancer) 04/2024 - 07/2004
27	Lung Neoplasms (Lung Cancer) 03/2024 - 01/2013
13	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 06/2014
3	Residual Neoplasm 01/2022 - 01/2021
3	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2020 - 03/2015
3	Inflammation (Inflammations) 01/2019 - 08/2004
2	Genomic Instability 04/2024 - 08/2023
2	Melanoma (Melanoma, Malignant) 04/2024 - 07/2013
2	Hematologic Neoplasms (Hematological Malignancy) 03/2024 - 03/2023
2	Adenocarcinoma of Lung 01/2017 - 11/2016
1	Immunoglobulin Light-chain Amyloidosis 10/2022
1	Multiple Myeloma 10/2022
1	Ataxia Telangiectasia (Louis Bar Syndrome) 01/2022
1	Head and Neck Neoplasms (Head and Neck Cancer) 12/2021
1	Disease Progression 01/2021
1	COVID-19 01/2021
1	Small Cell Carcinoma 01/2020
1	Stomach Neoplasms (Stomach Cancer) 01/2020
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2019
1	Carcinogenesis 01/2019
1	Brain Neoplasms (Brain Tumor) 01/2017
1	Neuroblastoma 02/2016

Drug/Important Bio-Agent (IBA)

8	Tyrosine Kinase InhibitorsIBA 12/2022 - 09/2016
7	Proteins (Proteins, Gene)FDA Link 04/2024 - 06/2014
6	lorlatinibIBA 01/2022 - 01/2018
6	ErbB Receptors (EGF Receptor)IBA 01/2022 - 03/2016
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 07/2013
5	Phosphotransferases (Kinase)IBA 01/2022 - 07/2013
4	DNA (Deoxyribonucleic Acid)IBA 04/2024 - 11/2021
4	Immune Checkpoint InhibitorsIBA 03/2024 - 09/2016
4	Anaplastic Lymphoma KinaseIBA 01/2022 - 01/2018
4	CrizotinibIBA 01/2021 - 01/2017
4	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2018 - 01/2013
3	LigandsIBA 04/2024 - 11/2016
3	Transcription Factors (Transcription Factor)IBA 04/2024 - 11/2016
3	AntibodiesIBA 03/2024 - 01/2020
3	NAD (NADH)IBA 04/2023 - 01/2023
3	Fatty Acids (Saturated Fatty Acids)IBA 01/2021 - 01/2019
3	ProstaglandinsIBA 09/2005 - 07/2004
2	Circulating Tumor DNAIBA 11/2023 - 01/2018
2	venetoclaxIBA 10/2022 - 02/2016
2	entrectinibIBA 01/2021 - 01/2019
2	RNA (Ribonucleic Acid)IBA 08/2020 - 01/2020
2	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 01/2020 - 01/2017
2	navitoclaxIBA 01/2018 - 03/2015
2	Mechanistic Target of Rapamycin Complex 1IBA 01/2014 - 07/2013
1	UracilIBA 04/2024
1	Cysteine (L-Cysteine)FDA Link 04/2024
1	CytidineIBA 04/2024
1	Cytidine DeaminaseIBA 08/2023
1	PlasticsIBA 06/2023
1	CollagenIBA 06/2023
1	Adenosine Diphosphate Ribose (ADP-Ribose)IBA 04/2023
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2023
1	Eukaryotic Initiation Factor-4F (EIF4F)IBA 01/2023
1	MicroRNAs (MicroRNA)IBA 12/2022
1	Proteasome InhibitorsIBA 10/2022
1	Bortezomib (Velcade)FDA Link 10/2022
1	Immunoglobulin Light Chains (Immunoglobulin Light Chain)IBA 10/2022
1	Focal Adhesion Protein-Tyrosine KinasesIBA 12/2021
1	AntioxidantsIBA 01/2021
1	Angiotensin-Converting Enzyme 2IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	AlginatesIBA 01/2021
1	sotorasibIBA 01/2021
1	cabozantinibIBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	adagrasibIBA 01/2021
1	capmatinibIBA 01/2021
1	Neoplasm Antigens (Tumor Antigens)IBA 01/2020
1	AntigensIBA 01/2020
1	EpitopesIBA 01/2020
1	Small Nuclear RNA (snRNA)IBA 01/2020
1	Adenosine Triphosphatases (ATPase)IBA 01/2020
1	Small Cytoplasmic RNAIBA 01/2020
1	Peptides (Polypeptides)IBA 01/2020
1	osimertinibIBA 01/2020
1	Metalloproteases (Metalloproteinases)IBA 01/2020
1	alectinibIBA 11/2019
1	Temozolomide (Temodar)FDA LinkGeneric 10/2019
1	olaparibIBA 10/2019
1	CytokinesIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2019
1	Tyrosine (L-Tyrosine)FDA Link 01/2019
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 01/2019
1	Type 1 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 1)IBA 01/2019
1	Proto-Oncogene Proteins c-bcl-2 (Proto Oncogene Proteins c bcl 2)IBA 12/2018
1	nazartinibIBA 01/2018
1	B7-H1 AntigenIBA 01/2017
1	Aurora Kinase AIBA 02/2016
1	MLN 8237IBA 02/2016
1	rociletinibIBA 07/2015
1	(5- (2,4- bis((3S)- 3- methylmorpholin- 4- yl)pyrido(2,3- d)pyrimidin- 7- yl)- 2- methoxyphenyl)methanolIBA 03/2015
1	Phosphatidylinositols (Phosphatidylinositol)IBA 06/2014

Therapy/Procedure

33	Therapeutics 03/2024 - 01/2013
4	Drug Therapy (Chemotherapy) 12/2021 - 03/2016
3	Aftercare (After-Treatment) 01/2020 - 07/2013
1	Immunotherapy 01/2020
1	Radiotherapy 01/2019